Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	-	24.61	22.83
Research & Development	-	73.95	88.19
Operating Expenses	-	98.55	111.03
Operating Income	64.26	-98.55	-111.03
Interest Expense / Income	-3.44	-1.97	-2.03
Other Expense / Income	11.02	3.83	5.94
Pretax Income	-16.82	-100.42	-114.94
Net Income	55.23	-100.42	-114.94
Free Cash Flow	77.19	-87.27	-101.17
EBITDA	-16.69	-98.29	-113.15
Depreciation & Amortization	3.57	4.09	3.82
EBIT	-20.26	-102.38	-116.97

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).